Evidence map›Paper›PMID 38980870›Full record

Trial reportThe Journal of clinical investigation2024

A fibroblast-dependent TGF-β1/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis.

Max L Cohen, Alexis N Brumwell, Tsung Che Ho, Kiana Garakani, Genevieve Montas, Darren Leong, Vivianne W Ding, Jeffrey A Golden, Binh N Trinh, David M Jablons and 6 more

Abstract readClinical Trial
In one paragraph

Trial report in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed.

  1. Trial
  2. Integrated Bioinformatics and Experimental Validation to Identify Shared Sialylation-Related Signatures in Emphysematous and Fibrotic Lung Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Article
  4. Multi-omics insights into the mechanisms and prognosis of IPF.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Max L CohenDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Alexis N BrumwellDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Tsung Che HoDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Kiana GarakaniDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Genevieve MontasDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Darren LeongDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Vivianne W DingDepartment of Surgery, Division of Cardiothoracic Surgery, and.
Jeffrey A GoldenDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Binh N TrinhDepartment of Surgery, Division of Cardiothoracic Surgery, and.
David M JablonsDepartment of Surgery, Division of Cardiothoracic Surgery, and.
Michael A MatthayDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Kirk D JonesDepartment of Pathology, University of California San Francisco, San Francisco, California, USA.
Paul J WoltersDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Ying WeiDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Harold A ChapmanDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.
Claude Jourdan Le SauxDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine.

Funding

MUTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASEST32HL007185 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David J Erle, LAURENCE HUANG · 1985 to 2026
$24.6M
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damageU01HL134766 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAPMAN, HAROLD A, KOTTON, DARRELL N. · 2016 to 2022
$8.1M
Program to promote lung regeneration and block fibrosisR35HL150767 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAPMAN, HAROLD A · 2020 to 2025
$5.8M
Reprogramming of type 2 alveolar epithelial cells in idiopathic pulmonary fibrosis and regulation by TGFb1.F32HL156356 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COHEN, MAX LOUIS · 2021 to 2023
$189k
NHLBI NIH HHS F32 HL156356NHLBI NIH HHS R35 HL150767NHLBI NIH HHS T32 HL007185NHLBI NIH HHS U01 HL134766
6 · The paper itself

Abstract

Reciprocal interactions between alveolar fibroblasts and epithelial cells are crucial for lung homeostasis, injury repair, and fibrogenesis, but underlying mechanisms remain unclear. To investigate, we administered the fibroblast-selective TGF-β1 signaling inhibitor epigallocatechin gallate (EGCG) to interstitial lung disease (ILD) patients undergoing diagnostic lung biopsy and conducted single-cell RNA-Seq on spare tissue. Biopsies from untreated patients showed higher fibroblast TGF-β1 signaling compared with nondisease donor or end-stage ILD tissues. In vivo, EGCG downregulated TGF-β1 signaling and several proinflammatory and stress pathways in biopsy samples. Notably, EGCG reduced fibroblast secreted frizzled-related protein 2 (sFRP2), an unrecognized TGF-β1 fibroblast target gene induced near type II alveolar epithelial cells (AEC2s) in situ. Using AEC2-fibroblast coculture organoids and precision-cut lung slices (PCLSs) from nondiseased donors, we found TGF-β1 signaling promotes a spread AEC2 KRT17+ basaloid state, whereupon sFRP2 then activates a mature cytokeratin 5+ (Krt5+) basal cell program. Wnt-receptor Frizzled 5 (Fzd5) expression and downstream calcineurin signaling were required for sFRP2-induced nuclear NFATc3 accumulation and KRT5 expression. These findings highlight stage-specific TGF-β1 signaling in ILD and the therapeutic potential of EGCG in reducing idiopathic pulmonary fibrosis-related (IPF-related) transcriptional changes and identify TGF-β1/noncanonical Wnt pathway crosstalk via sFRP2 as a mechanism for dysfunctional epithelial signaling in IPF/ILD.

Indexed as

FibroblastsIdiopathic Pulmonary FibrosisMetaplasiaTransforming Growth Factor beta1Wnt Signaling PathwayAlveolar Epithelial CellsAnimalsFemaleHumansMaleMembrane ProteinsMiceMiddle AgedMembrane ProteinsTGFB1 protein, humanTransforming Growth Factor beta1CytokinesFibrosisHuman stem cellsPulmonology

Identifiers

PMID38980870
PMCPMC11405054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.